MedTrace Logo

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

NCT04087707 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-02-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, pharmacokinetics, and pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy Japanese non-elderly and elderly participants

Conditions

  • Healthy Volunteer

Interventions

DRUG

Step 1: TS-142

Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

Step 2: TS-142

Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

Step 2: Placebo

Elderly participants will receive placebo once daily for 7 consective days

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • Japan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087707 on ClinicalTrials.gov